|
FDA Review Appears Positive for NPS’ Gattex Ahead of Advisory Meeting
The FDA appears to have a positive opinion of NPS Pharmaceuticals’ Gattex as a treatment for short bowel syndrome (SBS) patients, according to agency briefing documents.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives